CeriBell’s (CBLL) “Buy” Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of CeriBell (NASDAQ:CBLL) in a research note published on Wednesday morning,Benzinga reports. Canaccord Genuity Group currently has a $33.00 price target on the stock.

A number of other research firms have also recently issued reports on CBLL. TD Cowen lifted their price target on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a report on Monday, December 9th. Canaccord Genuity Group initiated coverage on CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price objective for the company. Bank of America initiated coverage on CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on CeriBell in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective for the company. Finally, William Blair initiated coverage on CeriBell in a research report on Tuesday, November 5th. They issued an “outperform” rating for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $32.60.

CeriBell Price Performance

CeriBell stock opened at $23.24 on Wednesday. The firm has a 50-day simple moving average of $23.34. CeriBell has a 12-month low of $18.69 and a 12-month high of $32.75.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million during the quarter, compared to analyst estimates of $17.55 million. As a group, sell-side analysts predict that CeriBell will post -2.46 EPS for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Institutional investors have recently modified their holdings of the stock. Legal & General Group Plc acquired a new position in shares of CeriBell during the 4th quarter worth about $32,000. Summit Investment Advisors Inc. acquired a new position in shares of CeriBell during the 4th quarter worth about $33,000. Tower Research Capital LLC TRC acquired a new position in shares of CeriBell during the 4th quarter worth about $37,000. BNP Paribas Financial Markets acquired a new position in shares of CeriBell during the 4th quarter worth about $43,000. Finally, PNC Financial Services Group Inc. acquired a new position in shares of CeriBell during the 4th quarter worth about $47,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.